5-Amino-1MQ and NNMT Inhibition in Metabolic Research

5-Amino-1MQ is the odd compound in the Thailand Peptides research catalogue. It is not a peptide. It is a small molecule (5-amino-1-methylquinolinium) that inhibits nicotinamide N-methyltransferase (NNMT). It is catalogued alongside peptides because it occupies a similar research space (metabolic research, body-composition research, aging biology) and is supplied through the same research-compound distribution channels. But the pharmacology is small-molecule pharmacology, not peptide pharmacology, and the research framing should reflect that distinction.

This article walks through the NNMT biology that justifies 5-Amino-1MQ’s research interest, the primary evidence for the compound specifically, and how it fits in the research landscape alongside peptide-class metabolic compounds.

The honest framing: small molecule, not peptide

Chemical structure:

• 5-Amino-1MQ: a quinoline heterocycle (a benzene fused to a pyridine) with an amine substituent at position 5 and a methyl group at position 1. Molecular formula C10H11N2+. Molecular weight ~159 Da.
• A typical research peptide: sequence of 4-50 amino acids linked by peptide bonds. Molecular weight 500-5000+ Da. Subject to proteolytic degradation, peptidase-sensitive, often requires injection administration.

5-Amino-1MQ is orally bioavailable (the small molecule size allows gastrointestinal absorption), not subject to peptidase degradation, and does not have the injection-handling requirements of peptides. This matters for research protocol design: the compound’s administration, storage, and pharmacokinetic profile are qualitatively different from the rest of the Thailand Peptides catalogue.

Why include it in a peptide catalogue? Two reasons, both practical rather than pharmacological:

1. Research-compound distribution channels. Supply chains for research-grade peptides and research-grade small molecules overlap substantially. Distributors serving researchers who work with peptides are often the same distributors serving researchers who work with compounds like 5-Amino-1MQ.
2. Research-space overlap. Researchers interested in metabolic research, body-composition research, and aging biology are often interested in multiple mechanism classes. Cataloguing 5-Amino-1MQ alongside peptide metabolic compounds makes it accessible to the same research audience.

The honesty disclosure matters because research protocols citing 5-Amino-1MQ should not treat it as a peptide. Mechanism, pharmacokinetics, and interactions all differ from peptide-class compounds.

The NNMT target and why it matters

Nicotinamide N-methyltransferase (NNMT) is an enzyme that catalyses the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), using S-adenosylmethionine (SAM) as the methyl donor. The reaction:

Nicotinamide + SAM → 1-Methylnicotinamide + S-Adenosylhomocysteine (SAH)

This reaction has three consequences that make NNMT metabolically interesting:

1. It consumes SAM, the cellular methyl donor. SAM is required for methylation of DNA, histones, neurotransmitters, and many small molecules. Elevated NNMT activity depletes the SAM pool, which has downstream effects on methylation-dependent processes throughout the cell.

2. It redirects nicotinamide away from NAD+ synthesis. Nicotinamide is a precursor for NAD+ synthesis via the salvage pathway. Every nicotinamide molecule methylated by NNMT is a nicotinamide molecule unavailable for NAD+ synthesis. NAD+ is the cellular redox cofactor that declines with age and in multiple metabolic diseases.

3. It generates 1-MNA, which is not metabolically inert. 1-MNA has its own signalling activity in some contexts, contributes to the urinary excretion of methyl groups, and has been associated with inflammation markers in clinical studies.

Park and colleagues’ 2024 Archives of Pharmaceutical Research review ⁵ is the best modern framing for NNMT as a therapeutic target. The review covers:

• NNMT’s role in multiple metabolic diseases (obesity, T2DM, NAFLD, cardiovascular disease)
• The expanding list of NNMT substrates and products
• Current small-molecule inhibitor development
• The therapeutic-target rationale across the disease spectrum

The NNMT-obesity connection: Kraus 2014 Nature

Before 5-Amino-1MQ, the NNMT-obesity connection was established by Kraus and colleagues’ 2014 Nature paper ². This work used siRNA-mediated NNMT knockdown in diet-induced obese mice and found:

• NNMT knockdown protected against weight gain on high-fat diets
• Metabolic profile improvements: better glucose tolerance, reduced hepatic steatosis
• Adipocyte-specific effects: altered lipid handling and energy metabolism
• No major off-target effects from the siRNA treatment at the tested doses

This paper established NNMT as a genetically-validated therapeutic target for obesity. The knockdown approach (acceptable in a research context) proved the concept; the pharmaceutical question was whether small-molecule inhibitors could replicate the effect.

Riederer and colleagues’ 2009 Atherosclerosis paper ⁴ had earlier characterised adipose tissue as a major source of NNMT, linking NNMT expression to homocysteine accumulation and by extension to cardiovascular risk. This set up the adipose-tissue-centric understanding of NNMT that the subsequent research built on.

Ehebauer and colleagues’ 2020 Life Sciences paper ³ added the metabolic regulation of NNMT expression itself: glucose availability regulates NNMT expression in adipocytes, creating a feedback relationship between metabolic state and NNMT activity. This matters for protocol design: NNMT inhibition may have different effects in different metabolic states.

5-Amino-1MQ: Neelakantan 2018

Neelakantan and colleagues’ 2018 Biochemical Pharmacology paper ¹ is the foundational 5-Amino-1MQ paper. The study characterised 5-Amino-1MQ as a selective, membrane-permeable small-molecule NNMT inhibitor and demonstrated its effects in diet-induced obesity in mice.

Key findings:

• 5-Amino-1MQ is selective for NNMT with minimal off-target effects on related methyltransferases at research-relevant concentrations
• Membrane permeability allows the compound to reach intracellular NNMT without requiring specialised delivery
• Oral bioavailability in mice supports practical administration routes
• Weight reduction in diet-induced obese mice with chronic 5-Amino-1MQ treatment, replicating the siRNA knockdown effect
• Adipose tissue effects including altered expression of energy-metabolism genes

The compound had been in development as a research tool before this publication; Neelakantan 2018 was the consolidated characterisation paper that established it as the reference NNMT inhibitor for research use.

Subsequent work has extended the NNMT-inhibitor research programme, including structural optimisation of 5-Amino-1MQ analogs, exploration of NNMT inhibition in other metabolic contexts (NAFLD, T2DM), and investigation of NNMT in non-adipose tissues where the enzyme also plays a role.

How the mechanism translates to research endpoints

For research protocols using 5-Amino-1MQ, the mechanism-to-endpoint chains are:

For body-composition research:

• 5-Amino-1MQ inhibits NNMT in adipocytes
• SAM and NAD+ pools are preserved
• Adipocyte metabolic flexibility improves
• Over weeks of chronic administration, body weight and fat mass reduce in preclinical models

For NAD+ research:

• NAD+ declines with age and in several metabolic diseases
• 5-Amino-1MQ prevents the NAD+ drain via NNMT activity
• Cellular NAD+ availability improves
• Downstream NAD+-dependent processes (sirtuin activity, mitochondrial function) are better supported

For methylation research:

• SAM is the cellular methyl donor
• NNMT activity depletes SAM
• 5-Amino-1MQ preserves SAM
• Methylation-dependent processes (DNA methylation, histone modification, neurotransmitter methylation) are better supported

Research protocols typically focus on one of these axes rather than all three simultaneously. The body-composition axis has the strongest evidence base; the NAD+ axis is actively researched; the methylation axis is conceptually supported but less empirically validated in the 5-Amino-1MQ literature specifically.

Comparison with peptide-class metabolic compounds

Five-Amino-1MQ’s position in the research landscape relative to peptide-class compounds:

vs. GLP-1-class compounds (semaglutide, tirzepatide, retatrutide):

• GLP-1 compounds work through appetite reduction and central satiety signalling
• 5-Amino-1MQ works through adipocyte energy metabolism
• Effect sizes in humans: GLP-1 class produces 15-24% body-weight reduction at Phase 3 scale; 5-Amino-1MQ clinical data in humans is far thinner
• Not competitive on fat-loss endpoints; different research space

vs. AOD-9604:

• AOD-9604 works through β3-AR-independent adipocyte lipolysis
• 5-Amino-1MQ works through NNMT/NAD+ preservation
• Both address adipocyte biology but via different mechanisms
• Neither compound has strong clinical-efficacy data for human body-composition endpoints
• Research protocols interested in adipocyte mechanism could theoretically combine them

vs. MOTS-c:

• MOTS-c activates AMPK via folate cycle modulation
• 5-Amino-1MQ preserves NAD+ via NNMT inhibition
• Both address mitochondrial and metabolic biology but through distinct pathways
• Complementary rather than redundant; some research programmes use both

vs. Epithalon:

• Epithalon targets telomerase and pineal function
• 5-Amino-1MQ targets NNMT and adipocyte metabolism
• Entirely different research questions; no obvious combination rationale unless protocol spans both aging biology and metabolic biology

Research protocol considerations

1. Oral administration is standard, not injection. 5-Amino-1MQ is a small molecule with oral bioavailability. Research protocols using the compound should administer orally (capsule or powder), not by injection. This is the most fundamental difference from peptide-class compounds in the catalogue.

2. Dose around 2-5 mg per day. Preclinical research used a range of doses; 2-5 mg/day is the commonly cited range in research protocol literature. Human clinical dose-response for specific endpoints is not well-characterised.

3. Chronic administration over weeks to months. The body-composition and NAD+ effects develop over time. Short-protocol research (days to a week or two) measures transient effects; sustained effects require longer exposure.

4. Target mechanism-specific endpoints. Body weight is an acceptable primary endpoint but coarse. NNMT activity (if accessible), NAD+/NADH ratio, SAM:SAH ratio, and 1-MNA urinary excretion are more mechanism-specific measures if the research infrastructure supports them.

5. Acknowledge the pharmacological category. Research protocols should be explicit that 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide. This affects expectations for PK/PD, interactions, handling, and scale-up to clinical use.

What the 5-Amino-1MQ literature does not yet settle

• Human clinical trial data is thin. Published work is primarily preclinical. Phase 2 or Phase 3 clinical programmes for body-composition or metabolic endpoints have not been reported at scale.
• Optimal dosing for specific research endpoints. The 2-5 mg/day range is inherited; systematic dose-finding in humans for NNMT inhibition at specific tissues has not been published.
• Long-term safety beyond research-context timeframes. Multi-year NNMT inhibition in humans has not been characterised. Mechanism reasoning suggests it should be well-tolerated; empirical long-term data is lacking.
• NNMT inhibition in specific tissue contexts. The compound inhibits NNMT systemically; whether tissue-selective NNMT modulation is possible with other compounds or formulations is an active research question.
• Combination with NAD+ supplementation. Whether adding 5-Amino-1MQ to NR or NMN supplementation produces additive effects, or whether the approaches are functionally redundant, has not been systematically tested.

Where to order

Buy 5-Amino-1MQ from Thailand Peptides through the Bangkok research desk. Research-grade oral powder, ≥98% HPLC purity, supplier COA on file, same-week Thailand delivery. Typical research-dose quantities are small given the oral route and modest per-day dose.

For the broader fat-loss research landscape including the peptide-class compounds, see best peptides for fat loss. For the hGH-fragment compound with a different mechanism in adipocyte biology, see the AOD-9604 lipolysis research deep-dive. For the broader GLP-1 class narrative against which 5-Amino-1MQ is positioned, see the GLP-1 research overview.